Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Disorders of Hemostasis01:24

Disorders of Hemostasis

915
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
915
Therapeutic Index01:13

Therapeutic Index

4.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

565
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
565

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant.

JAMA network open·2026
Same author

Targeting factor XI for venous thromboembolism prevention: a tale of 2 antibodies.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Case 6-2026: A 91-Year-Old Man with Shortness of Breath, Weight Loss, and Eosinophilia.

The New England journal of medicine·2026
Same author

Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis, and retrospective study.

Blood advances·2025
Same author

Population-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder.

Blood advances·2025
Same author

Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis.

Nature communications·2025

Related Experiment Video

Updated: Jul 4, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K

When Is It Preferable to Use Warfarin?

Pavan K Bendapudi1,2,3

  • 1Division of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston.

NEJM Evidence
|February 6, 2024
PubMed
Summary
This summary is machine-generated.

Direct oral anticoagulants (DOACs) are not always superior to warfarin, especially in certain patient groups. Understanding when warfarin remains preferable is crucial for optimal patient care and treatment decisions.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

Related Experiment Videos

Last Updated: Jul 4, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Direct oral anticoagulants (DOACs) have gained popularity for anticoagulation therapy.
  • However, recent data suggest DOACs may not be universally equivalent or superior to warfarin across all patient populations.
  • This challenges the assumption of DOAC superiority in every clinical scenario.

Purpose of the Study:

  • To address the clinical question of when warfarin is preferable to DOACs.
  • To analyze data that indicates limitations in DOAC equivalence or superiority.
  • To guide clinical decision-making regarding anticoagulation choices.

Main Methods:

  • Review of recent clinical data and studies comparing warfarin and DOACs.
  • Analysis of outcomes in specific patient populations where DOACs may not be optimal.
  • Synthesis of evidence to identify scenarios favoring warfarin use.

Main Results:

  • Data indicate that the equivalence or superiority of DOACs over warfarin cannot be assumed universally.
  • Certain patient populations show results that challenge the broad applicability of DOACs.
  • These findings necessitate a re-evaluation of anticoagulation strategies.

Conclusions:

  • Warfarin remains a valuable and sometimes preferable option for anticoagulation.
  • Clinical decisions must consider specific patient characteristics and available evidence.
  • Further research may be needed to delineate precise indications for warfarin versus DOACs.